Abbott Laboratories Q1 2024 Adj EPS $0.98 Beats $0.95 Estimate, Sales $9.964B Beat $9.880B Estimate
Portfolio Pulse from Benzinga Newsdesk
Abbott Laboratories (ABT) reported Q1 2024 adjusted EPS of $0.98, surpassing the $0.95 estimate, and sales of $9.964B, exceeding the $9.880B estimate. This represents a 4.85% decrease in EPS and a 2.23% increase in sales from the same period last year.
April 17, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott Laboratories reported a Q1 2024 EPS of $0.98, beating estimates, and sales of $9.964B, also above expectations.
Beating both EPS and sales estimates typically leads to positive investor sentiment and can result in a short-term stock price increase. The reported decrease in EPS year-over-year might temper some of the positive impact, but the overall beat on expectations and sales growth suggests a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100